Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: Results from HOST-REDUCE-POLYTECH-ACS trial.
Kyu-Sun LeeKeun-Ho ParkKyung Woo ParkSeung-Woon RhaDoyeon HwangJeehoon KangJung-Kyu HanHan-Mo YangHyun-Jae KangBon-Kwon KooNam-Ho LeeJay Young RhewKook Jin ChunYoung-Hyo LimJung Min BongJang-Whan BaeBong Ki LeeSeok-Yeon KimWon-Yong ShinHong-Seok LimKyungil ParkHyo-Soo KimPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
Prasugrel dose de-escalation compared with conventional therapy may reduce the risk of net clinical outcomes, mostly driven by a reduction in bleeding without an increase in ischemic events in patients with DM.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- antiplatelet therapy
- open label
- coronary artery disease
- coronary artery bypass grafting
- atrial fibrillation
- phase iii
- phase ii
- type diabetes
- study protocol
- clinical trial
- coronary artery bypass
- ischemia reperfusion injury
- stem cells
- wound healing
- heart failure
- oxidative stress
- adipose tissue
- cell therapy
- metabolic syndrome
- blood brain barrier